Collplant Biotechnologies Ltd (CLGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) has a cash flow conversion efficiency ratio of -0.309x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.88 Million) by net assets ($9.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Collplant Biotechnologies Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Collplant Biotechnologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Collplant Biotechnologies Ltd (CLGN) financial obligations for a breakdown of total debt and financial obligations.
Collplant Biotechnologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collplant Biotechnologies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Veganz Group AG
F:VEZ
|
-0.582x |
|
Dominion Minerals Ltd
AU:DLM
|
0.000x |
|
Envy Technologies Indonesia Tbk PT
JK:ENVY
|
0.019x |
|
Redsense Medical AB
ST:REDS
|
-0.053x |
|
Kingman Minerals Ltd
V:KGS
|
-0.096x |
|
West Cobar Metals Ltd
AU:WC1
|
-0.166x |
|
Bryah Resources Ltd
AU:BYH
|
-0.063x |
|
HUIJING HLDG.CO.LTD HD-01
F:3XU
|
N/A |
Annual Cash Flow Conversion Efficiency for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Collplant Biotechnologies Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Collplant Biotechnologies Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.46 Million | $-14.09 Million | -1.047x | -973.53% |
| 2023-12-31 | $28.34 Million | $-2.76 Million | -0.097x | +77.02% |
| 2022-12-31 | $32.28 Million | $-13.70 Million | -0.424x | -865.55% |
| 2021-12-31 | $45.12 Million | $2.50 Million | 0.055x | +105.58% |
| 2020-12-31 | $4.48 Million | $-4.45 Million | -0.994x | +28.73% |
| 2019-12-31 | $4.09 Million | $-5.70 Million | -1.395x | -445.61% |
| 2018-12-31 | $4.76 Million | $-1.22 Million | -0.256x | +86.54% |
| 2017-12-31 | $2.61 Million | $-4.97 Million | -1.900x | +49.26% |
| 2016-12-31 | $1.34 Million | $-5.02 Million | -3.745x | -152.18% |
| 2015-12-31 | $2.51 Million | $-3.72 Million | -1.485x | -64.13% |
| 2014-12-31 | $3.68 Million | $-3.33 Million | -0.905x | -84.26% |
| 2013-12-31 | $7.78 Million | $-3.82 Million | -0.491x | +46.58% |
| 2012-12-31 | $4.20 Million | $-3.86 Million | -0.919x | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more